Study:
Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy
Rationale:
n/a
Purpose:
This study enrolled men with prostate cancer who had failed hormone therapy (as shown by
rising prostate-specific antigen [PSA] levels) and who were about to start a new line of
chemotherapy. Blood was drawn prior to the patient receiving chemotherapy and then monthly
thereafter for up to 18 months or until disease progression, whichever occurred first. The
blood was tested to find circulating tumor cells (CTC) and to count them. The circulating
tumor cell levels were studied in relation to the patient`s overall survival. Serum was
also collected for PSA testing, and additional blood samples were drawn to test for
circulating endothelial cells and RNA was isolated for future gene expression testing.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Hormone Refractory Prostate Cancer
Prostate Cancer |
Procedure: Phlebotomy |
N/A |
Verified by
Immunicon
March, 2008
Sponsored by: Immunicon
Information provided by: Immunicon
ClinicalTrials.gov identifier: NCT00133900
Study Type: Interventional
Study Design: Cohort, Prospective
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Ken Pienta, MD., Principal Investigator
Derek Raghavan, M.D.., Principal Investigator